

# Anna K Nowak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6853997/publications.pdf>

Version: 2024-02-01

305  
papers

21,229  
citations

10956

71  
h-index

11288

136  
g-index

316  
all docs

316  
docs citations

316  
times ranked

20642  
citing authors

#	ARTICLE	IF	CITATIONS
1	The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 39-51.	0.5	3,162
2	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	5.1	776
3	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2021, 397, 375-386.	6.3	638
4	The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 990-1003.	0.5	628
5	Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. <i>Annals of Oncology</i> , 2004, 15, 257-260.	0.6	561
6	The International Association for the Study of Lung Cancer Lung Cancer Staging Project. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1675-1684.	0.5	550
7	The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1204-1223.	0.5	530
8	Mesothelin-family proteins and diagnosis of mesothelioma. <i>Lancet</i> , The, 2003, 362, 1612-1616.	6.3	516
9	Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells. <i>Journal of Immunology</i> , 2003, 170, 4905-4913.	0.4	401
10	The IASLC Lung Cancer Staging Project. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1515-1522.	0.5	357
11	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet Oncology</i> , The, 2017, 18, 1261-1273.	5.1	356
12	The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1109-1121.	0.5	342
13	The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 300-311.	0.5	338
14	Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. <i>Cancer Research</i> , 2003, 63, 4490-6.	0.4	311
15	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet</i> , The, 2017, 390, 1645-1653.	6.3	307
16	The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1618-1624.	0.5	299
17	The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 651-665.	0.5	211
18	A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. <i>British Journal of Cancer</i> , 2002, 87, 491-496.	2.9	210

#	ARTICLE	IF	CITATIONS
19	Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 264-272.	21.5	204
20	The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1433-1446.	0.5	201
21	Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target. <i>Carcinogenesis</i> , 2015, 36, 177-185.	1.3	184
22	The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. <i>Journal of Thoracic Oncology</i> , 2016, 11, 639-650.	0.5	182
23	Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. <i>Cancer Research</i> , 2002, 62, 2353-8.	0.4	175
24	The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2112-2119.	0.5	172
25	Systemic therapy for advanced hepatocellular carcinoma: a review. <i>European Journal of Cancer</i> , 2004, 40, 1474-1484.	1.3	171
26	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification. <i>Journal of Thoracic Oncology</i> , 2016, 11, 666-680.	0.5	170
27	Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. <i>Journal of Thoracic Disease</i> , 2013, 5, E254-307.	0.6	170
28	Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1449-1458.	2.8	169
29	The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the T component for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors. <i>Journal of Thoracic Oncology</i> , 2014, 9, S73-S80.	0.5	155
30	Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	147
31	The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2089-2099.	0.5	139
32	Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. <i>Journal of Neuro-Oncology</i> , 2010, 96, 393-402.	1.4	137
33	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC Tj ETQq1 1 0.784314 rgBT /Oncology, The, 2021, 22, 813-823.	5.1	132
34	Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4498-4504.	0.8	131
35	Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity. <i>PLoS ONE</i> , 2013, 8, e61895.	1.1	129
36	Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. <i>Thorax</i> , 2014, 69, 895-902.	2.7	128

#	ARTICLE	IF	CITATIONS
37	Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. <i>Lancet Oncology, The</i> , 2007, 8, 603-612.	5.1	127
38	Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1219-1228.	2.0	127
39	A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis. <i>Journal of Thoracic Oncology</i> , 2016, 11, 573-582.	0.5	126
40	A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. <i>BMC Cancer</i> , 2017, 17, 684.	1.1	125
41	Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1504-1513.	0.6	122
42	Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 3591-3600.	0.8	121
43	The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2100-2111.	0.5	120
44	The ITMIG/IASLC Thymic Epithelial Tumors Staging Project: A Proposed Lymph Node Map for Thymic Epithelial Tumors in the Forthcoming 8th Edition of the TNM Classification of Malignant Tumors. <i>Journal of Thoracic Oncology</i> , 2014, 9, S88-S96.	0.5	119
45	New approaches for mesothelioma: Biologics, vaccines, gene therapy, and other novel agents. <i>Seminars in Oncology</i> , 2002, 29, 82-96.	0.8	117
46	Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naïve patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 569-580.	5.2	117
47	Taxanes for adjuvant treatment of early breast cancer. <i>The Cochrane Library</i> , 2007, , CD004421.	1.5	111
48	Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. <i>Lancet Oncology, The</i> , 2020, 21, 1213-1223.	5.1	109
49	The impact of case discussion at a multidisciplinary team meeting on the treatment and survival of patients with inoperable non-small cell lung cancer. <i>Internal Medicine Journal</i> , 2009, 39, 838-841.	0.5	107
50	A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters. <i>Clinical Cancer Research</i> , 2010, 16, 2409-2417.	3.2	107
51	Targeting Aggressive Cancer Stem Cells in Glioblastoma. <i>Frontiers in Oncology</i> , 2015, 5, 159.	1.3	107
52	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. <i>Journal of Thoracic Oncology</i> , 2020, 15, 29-49.	0.5	106
53	Chemotherapy and immunotherapy: mapping the road ahead. <i>Current Opinion in Immunology</i> , 2016, 39, 23-29.	2.4	105
54	Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. <i>Lancet Oncology, The</i> , 2004, 5, 372-380.	5.1	102

#	ARTICLE	IF	CITATIONS
55	Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden. <i>Clinical Cancer Research</i> , 2011, 17, 1181-1189.	3.2	101
56	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 681-692.	0.5	101
57	The information and support needs of patients diagnosed with High Grade Glioma. <i>Patient Education and Counseling</i> , 2010, 79, 112-119.	1.0	100
58	Soluble mesothelin-related proteinâ€”A blood test for mesothelioma. <i>Lung Cancer</i> , 2005, 49, S109-S111.	0.9	99
59	Caring for someone with high-grade glioma: a time of rapid change for caregivers. <i>Palliative Medicine</i> , 2010, 24, 473-479.	1.3	97
60	A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. <i>Pathology</i> , 2013, 45, 44-48.	0.3	97
61	Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. <i>Lancet Oncology</i> , The, 2013, 14, 543-551.	5.1	93
62	Assessing Quality of Life During Chemotherapy for Pleural Mesothelioma: Feasibility, Validity, and Results of Using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. <i>Journal of Clinical Oncology</i> , 2004, 22, 3172-3180.	0.8	91
63	Combined chemoimmunotherapy of solid tumours: Improving vaccines?. <i>Advanced Drug Delivery Reviews</i> , 2006, 58, 975-990.	6.6	90
64	A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1449-1456.	0.5	89
65	Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 1444-1448.	0.8	85
66	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667.	0.5	85
67	Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1). <i>Journal of Thoracic Oncology</i> , 2018, 13, 1012-1021.	0.5	85
68	Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 2343-2356.	2.0	84
69	Cyclophosphamide Chemotherapy Sensitizes Tumor Cells to TRAIL-Dependent CD8 T Cell-Mediated Immune Attack Resulting in Suppression of Tumor Growth. <i>PLoS ONE</i> , 2009, 4, e6982.	1.1	82
70	Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMANDâ€”A Double-Blind, Randomized, Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 790-798.	0.8	79
71	Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3132-3141.	0.8	78
72	A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. <i>Annals of Oncology</i> , 2015, 26, 2483-2490.	0.6	76

#	ARTICLE	IF	CITATIONS
73	Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1784-1791.	0.5	75
74	Diagnosing cancer in the bush: a mixed-methods study of symptom appraisal and help-seeking behaviour in people with cancer from rural Western Australia. <i>Family Practice</i> , 2013, 30, 294-301.	0.8	73
75	Harnessing the immune response to treat cancer. <i>Oncogene</i> , 2010, 29, 6301-6313.	2.6	72
76	Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules. <i>Journal of Pathology</i> , 2018, 245, 209-221.	2.1	70
77	The Use of Agonistic Anti-CD40 Therapy in Treatments for Cancer. <i>International Reviews of Immunology</i> , 2012, 31, 246-266.	1.5	69
78	Patient and caregiver perceptions of communication of prognosis in high grade glioma. <i>Journal of Neuro-Oncology</i> , 2011, 104, 315-322.	1.4	68
79	Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1010-1016.	0.5	67
80	Progress in the Management of Malignant Pleural Mesothelioma in 2017. <i>Journal of Thoracic Oncology</i> , 2018, 13, 606-623.	0.5	67
81	Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer. <i>British Journal of Cancer</i> , 2015, 113, 1677-1686.	2.9	64
82	Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. <i>European Journal of Immunology</i> , 2015, 45, 49-59.	1.6	64
83	Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations. <i>Scientific Reports</i> , 2015, 5, 12298.	1.6	63
84	Whole brain radiotherapy after local treatment of brain metastases in melanoma patients - a randomised phase III trial. <i>BMC Cancer</i> , 2011, 11, 142.	1.1	62
85	The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2082-2088.	0.5	61
86	An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2012, 30, 387-394.	1.2	59
87	Cosmesis and Breast-Related Quality of Life Outcomes After Intraoperative Radiation Therapy for Early Breast Cancer: A Substudy of the TARGIT-A Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 55-64.	0.4	59
88	The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. <i>Neuro-Oncology</i> , 2015, 17, 1589-1598.	0.6	57
89	Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses. <i>Frontiers in Immunology</i> , 2020, 11, 587014.	2.2	56
90	Predictors of distress and poorer quality of life in High Grade Glioma patients. <i>Patient Education and Counseling</i> , 2015, 98, 525-532.	1.0	55

#	ARTICLE	IF	CITATIONS
91	Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. <i>Oncolimmunology</i> , 2016, 5, e1066062.	2.1	55
92	Use of tamoxifen in advanced-stage hepatocellular carcinoma. <i>Cancer</i> , 2005, 103, 1408-1414.	2.0	54
93	Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies. <i>British Journal of Cancer</i> , 2012, 107, 1107-1115.	2.9	54
94	Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 223.	2.2	54
95	The Potential Role of Exercise in Neuro-Oncology. <i>Frontiers in Oncology</i> , 2015, 5, 85.	1.3	52
96	A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. <i>Lung Cancer</i> , 2013, 81, 422-427.	0.9	51
97	The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 801-809.	0.5	49
98	Clinical management and survival outcomes of gliosarcomas in the era of multimodality therapy. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 478-481.	0.8	48
99	A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. <i>Oncologist</i> , 2019, 24, 521-528.	1.9	47
100	Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. <i>British Journal of Cancer</i> , 2008, 98, 1562-1569.	2.9	46
101	Distress and psychological morbidity do not reduce over time in carers of patients with high-grade glioma. <i>Supportive Care in Cancer</i> , 2017, 25, 887-893.	1.0	46
102	Malignant pleural mesothelioma: an update on diagnosis and treatment options. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 275-288.	1.0	45
103	Do carer's levels of unmet needs change over time when caring for patients diagnosed with high-grade glioma and how are these needs correlated with distress?. <i>Supportive Care in Cancer</i> , 2018, 26, 275-286.	1.0	44
104	The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates. <i>Journal of Clinical Oncology</i> , 2013, 31, 3565-3571.	0.8	43
105	Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma. <i>British Journal of Cancer</i> , 2013, 109, 1813-1820.	2.9	42
106	Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future. <i>Annals of Cardiothoracic Surgery</i> , 2012, 1, 508-15.	0.6	42
107	Imaging in pleural mesothelioma: A review of Imaging Research Presented at the 9th International Meeting of the International Mesothelioma Interest Group. <i>Lung Cancer</i> , 2010, 70, 1-6.	0.9	41
108	Enhancing the efficacy of immunotherapy using radiotherapy. <i>Clinical and Translational Immunology</i> , 2020, 9, e1169.	1.7	40

#	ARTICLE	IF	CITATIONS
109	OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result. <i>Journal of Thoracic Oncology</i> , 2018, 13, S338-S339.	0.5	39
110	Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 584423.	2.2	39
111	Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group. <i>Lung Cancer</i> , 2016, 101, 48-58.	0.9	38
112	Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2000-2000.	0.8	38
113	CT, RECIST, and malignant pleural mesothelioma. <i>Lung Cancer</i> , 2005, 49, S37-S40.	0.9	37
114	Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile?. <i>European Journal of Cancer</i> , 2010, 46, 1800-1807.	1.3	37
115	Combination immune checkpoint blockade as an effective therapy for mesothelioma. <i>Oncolmmunology</i> , 2018, 7, e1494111.	2.1	37
116	Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF). <i>Scientific Reports</i> , 2019, 9, 2905.	1.6	34
117	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. <i>Neuro-Oncology</i> , 2021, 23, 1547-1559.	0.6	34
118	Randomized Controlled Trial of Shared Care for Patients With Cancer Involving General Practitioners and Cancer Specialists. <i>Journal of Oncology Practice</i> , 2015, 11, 349-355.	2.5	33
119	Diagnosing cancer in the bush: a mixed methods study of GP and specialist diagnostic intervals in rural Western Australia. <i>Family Practice</i> , 2013, 30, 541-550.	0.8	32
120	Taxanes for adjuvant treatment of early breast cancer. <i>The Cochrane Library</i> , 2019, 9, CD004421.	1.5	32
121	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. <i>Acta Neuropathologica</i> , 2021, 141, 945-957.	3.9	32
122	Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy*. <i>ANZ Journal of Surgery</i> , 2009, 79, 734-738.	0.3	31
123	MexTAg mice exposed to asbestos develop cancer that faithfully replicates key features of the pathogenesis of human mesothelioma. <i>European Journal of Cancer</i> , 2011, 47, 151-161.	1.3	31
124	Observer Variability in Mesothelioma Tumor Thickness Measurements: Defining Minimally Measurable Lesions. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1187-1194.	0.5	31
125	Cosmetic outcome as rated by patients, doctors, nurses and BCCT.core software assessed over 5Âyears in a subset of patients in the TARGIT-A Trial. <i>Radiation Oncology</i> , 2018, 13, 68.	1.2	31
126	Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial. <i>Thorax</i> , 2019, 74, 354-361.	2.7	31



#	ARTICLE	IF	CITATIONS
127	Contribution of the immune system to the chemotherapeutic response. <i>Seminars in Immunopathology</i> , 2011, 33, 353-367.	2.8	30
128	Thymidylate Synthase and Foyl-Polyglutamate Synthase Are Not Clinically Useful Markers of Response to Pemetrexed in Patients with Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2013, 8, 469-477.	0.5	30
129	Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response. <i>Oncotarget</i> , 2017, 8, 19803-19813.	0.8	30
130	Disease volumes as a marker for patient response in malignant pleural mesothelioma. <i>Annals of Oncology</i> , 2013, 24, 999-1005.	0.6	29
131	Antiangiogenic Strategies in Mesothelioma. <i>Frontiers in Oncology</i> , 2020, 10, 126.	1.3	29
132	Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT. <i>Lung Cancer</i> , 2015, 90, 55-60.	0.9	28
133	PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. <i>Lung Cancer</i> , 2016, 93, 9-16.	0.9	27
134	The Improving Rural Cancer Outcomes Trial: a cluster-randomised controlled trial of a complex intervention to reduce time to diagnosis in rural cancer patients in Western Australia. <i>British Journal of Cancer</i> , 2017, 117, 1459-1469.	2.9	27
135	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2527-2535.	3.2	27
136	Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen. <i>Oncolmmunology</i> , 2015, 4, e1011492.	2.1	26
137	Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8502-8502.	0.8	26
138	Carers of patients with high-grade glioma report high levels of distress, unmet needs, and psychological morbidity during patient chemoradiotherapy. <i>Neuro-Oncology Practice</i> , 2016, 3, 105-112.	1.0	25
139	Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 540-552.	5.1	25
140	Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2013, 8, 478-486.	0.5	22
141	Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment. <i>Oncolmmunology</i> , 2019, 8, e1641390.	2.1	22
142	DREAM: A phase II study of durvalumab with first line chemotherapy in mesotheliomaâ€”First results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8503-8503.	0.8	22
143	Optimization of Response Classification Criteria for Patients with Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1728-1734.	0.5	21
144	Peripheral CD8+ TÂcell proliferation is prognostic for patients with advanced thoracic malignancies. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 529-539.	2.0	21

#	ARTICLE	IF	CITATIONS
145	A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2020, 140, 87-92.	0.9	21
146	The Antioxidants Vitamins A and E and Selenium Do Not Reduce the Incidence of Asbestos-Induced Disease in a Mouse Model of Mesothelioma. <i>Nutrition and Cancer</i> , 2012, 64, 315-322.	0.9	20
147	Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes. <i>Oncolmunology</i> , 2016, 5, e1082028.	2.1	20
148	Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA2000-LBA2000.	0.8	20
149	Tamoxifen for hepatocellular carcinoma. <i>The Cochrane Library</i> , 2004, , CD001024.	1.5	19
150	Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study. <i>Journal of Clinical Pathology</i> , 2014, 67, 550-555.	1.0	19
151	Protocol for the Care-IS Trial: a randomised controlled trial of a supportive educational intervention for carers of patients with high-grade glioma (HGG). <i>BMJ Open</i> , 2015, 5, e009477.	0.8	19
152	Bilateral murine tumor models for characterizing the response to immune checkpoint blockade. <i>Nature Protocols</i> , 2020, 15, 1628-1648.	5.5	19
153	Darkroom hepatitis after exposure to hydroquinone. <i>Lancet, The</i> , 1995, 345, 1187.	6.3	18
154	The Improving Rural Cancer Outcomes (IRCO) Trial: a factorial cluster-randomised controlled trial of a complex intervention to reduce time to diagnosis in rural patients with cancer in Western Australia: a study protocol. <i>BMJ Open</i> , 2014, 4, e006156-e006156.	0.8	18
155	Imaging in pleural mesothelioma: A review of the 12th International Conference of the International Mesothelioma Interest Group. <i>Lung Cancer</i> , 2015, 90, 148-154.	0.9	18
156	Immune checkpoint inhibition for the treatment of mesothelioma. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 697-706.	1.4	18
157	Measuring financial toxicity in Australian cancer patients – Validation of the COmprehensive Score for financial Toxicity (FACT COST) measuring financial toxicity in Australian cancer patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 377-387.	0.7	18
158	Multimodality Imaging Review of Malignant Pleural Mesothelioma Diagnosis and Staging. <i>PET Clinics</i> , 2011, 6, 275-297.	1.5	17
159	Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile?. <i>Lung Cancer</i> , 2011, 72, 213-218.	0.9	17
160	Intraoperative radiotherapy for early breast cancer: do health professionals choose convenience or risk?. <i>Radiation Oncology</i> , 2014, 9, 33.	1.2	17
161	Evolving management of low grade glioma: No consensus amongst treating clinicians. <i>Journal of Clinical Neuroscience</i> , 2016, 23, 81-87.	0.8	17
162	LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2017, 18, 589-593.	1.1	17

#	ARTICLE	IF	CITATIONS
163	Elderly dendritic cells respond to LPS/IFN- $\gamma$ and CD40L stimulation despite incomplete maturation. PLoS ONE, 2018, 13, e0195313.	1.1	17
164	A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET).. Journal of Clinical Oncology, 2013, 31, 2017-2017.	0.8	17
165	Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?. Future Oncology, 2014, 10, 1137-1145.	1.1	16
166	Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation. Oncology Letters, 2015, 9, 2063-2067.	0.8	16
167	Restoration of defective cross-presentation in tumors by gemcitabine. Oncoimmunology, 2015, 4, e1005501.	2.1	16
168	Novel Targeted Therapies and Vaccination Strategies for Mesothelioma. Current Treatment Options in Oncology, 2011, 12, 149-162.	1.3	15
169	First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. BMC Research Notes, 2015, 8, 192.	0.6	15
170	Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma. Journal of Neuro-Oncology, 2017, 133, 623-631.	1.4	15
171	Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee and International Association for the Study of Lung Cancer and Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. Journal of Thoracic Oncology, 2019, 14, 1718-1731.	0.5	15
172	Exploring sleep disturbance among adults with primary or secondary malignant brain tumors and their caregivers. Neuro-Oncology Practice, 2021, 8, 48-59.	1.0	15
173	Management of Advanced Pleural Mesothelioma At the Crossroads. JCO Oncology Practice, 2022, 18, 116-124.	1.4	15
174	Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma. Tissue Antigens, 2009, 74, 1-10.	1.0	14
175	Feasibility Testing and Refinement of a Supportive Educational Intervention for Carers of Patients with High-Grade Glioma a Pilot Study. Journal of Cancer Education, 2018, 33, 967-975.	0.6	14
176	Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma. Seminars in Oncology, 2019, 46, 145-154.	0.8	14
177	Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life. European Journal of Clinical Nutrition, 2019, 73, 1412-1421.	1.3	14
178	Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used. Cancer Immunology, Immunotherapy, 2021, 70, 3249-3258.	2.0	14
179	Effect of NSAIDs and COX-2 inhibitors on the incidence and severity of asbestos-induced malignant mesothelioma: Evidence from an animal model and a human cohort. Lung Cancer, 2014, 86, 29-34.	0.9	13
180	Immunological checkpoint inhibitors enter adolescence. Lancet Oncology, The, 2013, 14, 1035-1037.	5.1	12

#	ARTICLE	IF	CITATIONS
181	An Oasis in the Hospital. <i>Journal of Holistic Nursing</i> , 2014, 32, 250-260.	0.6	12
182	Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial. <i>Neuro-Oncology Practice</i> , 2017, 4, 171-181.	1.0	12
183	A systematic review and meta-analysis of utility estimates in melanoma. <i>British Journal of Dermatology</i> , 2018, 178, 384-393.	1.4	12
184	Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery. <i>Journal of Thoracic Oncology</i> , 2019, 14, 288-293.	0.5	12
185	Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 592-606.	1.8	11
186	Continuing or ceasing bevacizumab at disease progression: Results from the CABARET study, a prospective randomized phase II trial in patients with recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2003-2003.	0.8	10
187	The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET). <i>Cancer</i> , 2017, 123, 3576-3582.	2.0	9
188	Malignant Pleural Effusionsâ€”A Window Into Local Anti-Tumor T Cell Immunity?. <i>Frontiers in Oncology</i> , 2021, 11, 672747.	1.3	9
189	NIPLU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma. <i>Journal of Translational Medicine</i> , 2021, 19, 232.	1.8	9
190	Protocol of DREAM3R: DuRvalumab with chemotherapy as first-line treatment in advanced pleural Mesotheliomaâ€”a phase 3 randomised trial. <i>BMJ Open</i> , 2022, 12, e057663.	0.8	9
191	First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. <i>Lung Cancer</i> , 2022, 167, 8-16.	0.9	9
192	Clinical evidence for synergy between immunotherapy and radiotherapy (<sc>SITAR</sc>). <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 881-895.	0.9	9
193	A prospective study of surgical patterns of care for high grade glioma in the current era of multimodality therapy. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 227-231.	0.8	8
194	Combining chemotherapy and checkpoint blockade in thoracic cancer: how to proceed?. <i>Lung Cancer Management</i> , 2014, 3, 443-457.	1.5	8
195	Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters. <i>BMC Cancer</i> , 2017, 17, 417.	1.1	8
196	Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1704-1717.	0.5	8
197	The role of psychosocial support in the experiences of people living with advanced cancer: A qualitative exploration of patients' perspectives. <i>Psycho-Oncology</i> , 2021, 30, 287-295.	1.0	8
198	Patients and carers' perspectives of participating in a pilot tailored exercise program during chemoradiotherapy for high grade glioma: A qualitative study. <i>European Journal of Cancer Care</i> , 2021, 30, e13453.	0.7	8

#	ARTICLE	IF	CITATIONS
199	Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.. Journal of Clinical Oncology, 2016, 34, LBA2000-LBA2000.	0.8	8
200	Current chemotherapeutic treatment of malignant pleural mesothelioma. Expert Opinion on Pharmacotherapy, 2004, 5, 2441-2449.	0.9	7
201	Cisplatin and gemcitabine in malignant mesothelioma. Annals of Oncology, 2005, 16, 1711.	0.6	7
202	Small cell lung cancer presenting with paraneoplastic limbic encephalitis. Asia-Pacific Journal of Clinical Oncology, 2011, 7, 180-184.	0.7	7
203	Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors. BMC Research Notes, 2018, 11, 864.	0.6	7
204	Increased interdigitation zone visibility on optical coherence tomography following systemic fibroblast growth factor receptor 1 tyrosine kinase inhibitor anticancer therapy. Clinical and Experimental Ophthalmology, 2021, 49, 579-590.	1.3	7
205	ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma.. Journal of Clinical Oncology, 2017, 35, TPS8582-TPS8582.	0.8	7
206	Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy. Frontiers in Oncology, 2022, 12, 849793.	1.3	7
207	The Ecological Association between Asbestos Consumption and Asbestos-Related Diseases 15 Years Later. Environmental Health Perspectives, 2022, 130, .	2.8	7
208	Immunotherapy trials in mesothelioma â€” promising results, but donâ€™t stop here. Nature Reviews Clinical Oncology, 2019, 16, 726-728.	12.5	6
209	Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM). Journal of Patient-Reported Outcomes, 2019, 3, 34.	0.9	6
210	Alveolar adenoma of the lung: multidisciplinary case discussion and review of the literature. Journal of Thoracic Disease, 2020, 12, 6847-6853.	0.6	6
211	PathoFusion: An Open-Source AI Framework for Recognition of Pathomorphological Features and Mapping of Immunohistochemical Data. Cancers, 2021, 13, 617.	1.7	6
212	Statins Do Not Alter the Incidence of Mesothelioma in Asbestos Exposed Mice or Humans. PLoS ONE, 2014, 9, e103025.	1.1	6
213	Does CA125 binding to mesothelin impact the detection of malignant mesothelioma?. Lung Cancer, 2013, 80, 39-44.	0.9	5
214	Dietary Vitamin D Supplementation Does Not Reduce the Incidence or Severity of Asbestos-Induced Mesothelioma in a Mouse Model. Nutrition and Cancer, 2014, 66, 383-387.	0.9	5
215	Chemoimmunotherapy: still waiting for the magic to happen. Lancet Oncology, The, 2014, 15, 780-781.	5.1	5
216	Management of glioblastoma: an Australian perspective. Chinese Clinical Oncology, 2021, 10, 42-42.	0.4	5

#	ARTICLE	IF	CITATIONS
217	Sleep disturbance in people with brain tumours and caregivers: a survey of healthcare professionalsâ€™ views and current practice. <i>Supportive Care in Cancer</i> , 2021, 29, 1497-1508.	1.0	5
218	Care plus study: a multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer: a study protocol. <i>BMC Health Services Research</i> , 2021, 21, 513.	0.9	5
219	DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesotheliomaâ€™A phase 3 randomized trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS8586-TPS8586.	0.8	5
220	Supportive care of patients diagnosed with high grade glioma and their carers in Australia. <i>Journal of Neuro-Oncology</i> , 2022, 157, 475-485.	1.4	5
221	EGFR mutation testing in NSCLC: Patterns of care and outcomes in Western Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 66-71.	0.7	4
222	A Multimodality Imaging Review of Malignant Pleural Mesothelioma Response Assessment. <i>PET Clinics</i> , 2011, 6, 299-311.	1.5	4
223	Radiotherapy in the management of highâ€™grade gliomas diagnosed in Western Australia: A patterns of care study. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012, 56, 109-115.	0.9	4
224	Marked functional improvement after combined chemoradiotherapy for cervical spine glioblastoma causing quadriplegia in an adolescent. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013202791-bcr2013202791.	0.2	4
225	Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan. <i>Trials</i> , 2019, 20, 477.	0.7	4
226	Cost-Effectiveness of Subsequent Whole-Brain Radiotherapy or Hippocampal-Avoidant Whole-Brain Radiotherapy Versus Stereotactic Radiosurgery or Surgery Alone for Treatment of Melanoma Brain Metastases. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 679-687.	1.0	4
227	Barriers and potential solutions to international collaboration in neuroâ€™oncology clinical trials: Challenges from the Australian perspective. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 259-266.	0.7	4
228	Repeatability of image features extracted from FET PET in application to post-surgical glioblastoma assessment. <i>Physical and Engineering Sciences in Medicine</i> , 2021, 44, 1131-1140.	1.3	4
229	Understanding sleep disturbance in the context of malignant brain tumors: a qualitative analysis. <i>Neuro-Oncology Practice</i> , 2021, 8, 179-189.	1.0	4
230	A multicenter, 3-arm, open-label, phase IIa clinical trial to evaluate the safety and efficacy of tanibirumab (VEGFR2 mAb), in patients with recurrent glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2017, 35, e13522-e13522.	0.8	4
231	Immune checkpoint inhibitor therapy for malignant pleural mesothelioma. <i>Lung Cancer</i> , 2021, 162, 162-168.	0.9	4
232	â€™Who can I ring? Where can I go?â€™ Living with advanced cancer whilst navigating the health system: a qualitative study. <i>Supportive Care in Cancer</i> , 2022, 30, 6817-6826.	1.0	4
233	79 Use of 18F-FDG PET imaging in staging and prediction of survival for malignant pleural mesothelioma (MPM). <i>Lung Cancer</i> , 2006, 54, S19.	0.9	3
234	Immune Stimulatory Features of Classical Chemotherapy. , 2007, , 235-256.		3

#	ARTICLE	IF	CITATIONS
235	Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 55-67.	0.7	3
236	Asbestos exposure: challenges for Australian clinicians. <i>Medical Journal of Australia</i> , 2016, 204, 48-49.	0.8	3
237	Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial. <i>Journal of Clinical Neuroscience</i> , 2019, 70, 157-163.	0.8	3
238	Patient preferences for adjuvant radiotherapy in early breast cancer are strongly influenced by treatment received through random assignment. <i>European Journal of Cancer Care</i> , 2019, 28, e12985.	0.7	3
239	Repeatability of Quantitative 18F-FET PET in Glioblastoma. <i>Biomedical Physics and Engineering Express</i> , 2021, 7, 035020.	0.6	3
240	Effect of Chemotherapy on the Tumor Microenvironment and Anti-tumor Immunity. , 2013, , 1-28.		3
241	Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9500-9500.	0.8	3
242	Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	3
243	Phase II trials in mesothelioma: An increasing challenge. <i>Lung Cancer</i> , 2005, 50, 87-90.	0.9	2
244	Management of malignant pleural mesothelioma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2007, 3, 177-186.	0.7	2
245	Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 350-356.	0.7	2
246	S59 Chemo-immunotherapy of mesothelioma: depletion of established, suppressive CD4 T cells is critical to achieving cures in a murine model. <i>Thorax</i> , 2011, 66, A29-A29.	2.7	2
247	Immune Stimulatory Features of Classical Chemotherapy. , 2013, , 395-414.		2
248	Response to comment on "Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma". <i>British Journal of Cancer</i> , 2014, 111, 2377-2377.	2.9	2
249	PL02.09 Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial. <i>Journal of Thoracic Oncology</i> , 2018, 13, S186.	0.5	2
250	2130 Nintedanib + pemetrexed/cisplatin in malignant pleural mesothelioma (MPM): Phase II biomarker data from the LUME Meso study. <i>Journal of Thoracic Oncology</i> , 2018, 13, S128.	0.5	2
251	Driving innovation through collaboration: development of clinical annotation datasets for brain cancer biobanking. <i>Neuro-Oncology Practice</i> , 2020, 7, 31-37.	1.0	2
252	Voluntary exercise in mesothelioma: effects on tumour growth and treatment response in a murine model. <i>BMC Research Notes</i> , 2020, 13, 435.	0.6	2

#	ARTICLE	IF	CITATIONS
253	Barriers to managing sleep disturbance in people with malignant brain tumours and their caregivers: a qualitative analysis of healthcare professionals' perception. Supportive Care in Cancer, 2021, 29, 3865-3876.	1.0	2
254	Heterogeneity of treatment effects in malignant pleural mesothelioma – Authors' reply. Lancet, The, 2021, 398, 302.	6.3	2
255	Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2016, 34, TPS8574-TPS8574.	0.8	2
256	A randomized, placebo-controlled study of amatuximab in combination with pemetrexed and cisplatin (P/C) as front-line therapy for subjects with malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2016, 34, TPS8577-TPS8577.	0.8	2
257	LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided Therapies at relapse: Protocol for a pilot study. BMJ Open, 2021, 11, e054075.	0.8	2
258	Bevacizumab-related Remote Intracranial Hemorrhages After Glioma Resection. Neurosurgery Quarterly, 2014, 24, 167-169.	0.1	1
259	New directions in mesothelioma treatment. Lung Cancer Management, 2015, 4, 299-307.	1.5	1
260	Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e359-e365.	0.7	1
261	Reply to K. Masuda et al. Journal of Clinical Oncology, 2019, 37, 2294-2295.	0.8	1
262	Tamoxifen for hepatocellular carcinoma. The Cochrane Library, 2020, 2020, CD001024.	1.5	1
263	Incorporating competing risk theory into evaluations of changes in cancer survival: making the most of cause of death and routinely linked sociodemographic data. BMC Public Health, 2020, 20, 1002.	1.2	1
264	A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers. Expert Review of Anticancer Therapy, 2021, 21, 465-474.	1.1	1
265	What matters for people with brain cancer? Selecting clinical quality indicators for an Australian Brain Cancer Registry. Neuro-Oncology Practice, 2022, 9, 68-78.	1.0	1
266	Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study.. Journal of Clinical Oncology, 2014, 32, TPS7612-TPS7612.	0.8	1
267	Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2017, 35, 8506-8506.	0.8	1
268	Phase Ib study of olinvacimab (O) with pembrolizumab (P) in patients with recurrent glioblastoma (rGBM).. Journal of Clinical Oncology, 2020, 38, e14545-e14545.	0.8	1
269	Title is missing!. , 2017, , .		1
270	Imaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest Group. Lung Cancer, 2022, 164, 76-83.	0.9	1



#	ARTICLE	IF	CITATIONS
271	Clinical trials in malignant pleural mesothelioma in Australasia. Lung Cancer, 2005, 49, S113-S116.	0.9	0
272	30 Functional and patient-rated endpoints in clinical trials. Lung Cancer, 2006, 54, S7-S8.	0.9	0
273	196 The current status of mesothelioma clinical trials in Australasia. Lung Cancer, 2006, 54, S47.	0.9	0
274	234 MUC1 in malignant mesothelioma. Lung Cancer, 2006, 54, S57.	0.9	0
275	Bisphosphonates for prevention of bone loss in women with early breast cancer. The Cochrane Library, 2009, , .	1.5	0
276	A Randomised Phase II Study of Carboplatin and Bevacizumab in Recurrent Glioblastoma Multiforme (CABARET STUDY). Cooperative Trials Group For Neuro-Oncology (COGNO). Annals of Oncology, 2012, 23, ix151.	0.6	0
277	Randomized Trial of Whole-Brain Radiation Therapy in Melanoma Brain Metastases: First Interim Analysis. International Journal of Radiation Oncology Biology Physics, 2014, 90, S313-S314.	0.4	0
278	Neurosurgical Issues Related to Bevacizumab Use in the Management of Glioblastoma. Neurosurgery Quarterly, 2015, 25, 255-259.	0.1	0
279	Novel insights into the pathophysiology and treatment of malignant pleural mesothelioma. Lung Cancer Management, 2015, 4, 249-259.	1.5	0
280	Compliance with reporting guidelines by Australian pathologists: an audit of the quality of histopathology reporting in high-grade glioma. Neuro-Oncology Practice, 2016, 3, 97-104.	1.0	0
281	MS 08.04 Immunotherapy in MPM. Journal of Thoracic Oncology, 2017, 12, S1687-S1688.	0.5	0
282	Pembrolizumab (pembro) for relapsed malignant pleural mesothelioma (MPM): Outcomes in real-life setting in Australia (AUS) and Switzerland (CH). Annals of Oncology, 2017, 28, xi8.	0.6	0
283	Bisphosphonates for prevention of bone loss in women with early breast cancer. The Cochrane Library, 0, , .	1.5	0
284	Malignant Mesothelioma. , 2018, , 536-549.e4.		0
285	MS25.01 Impact of Tumor Volume on Outcome: What Are the Limitations?. Journal of Thoracic Oncology, 2018, 13, S293-S294.	0.5	0
286	Young adults diagnosed with high grade gliomas: Patterns of care, outcomes, and impact on employment. Journal of Clinical Neuroscience, 2019, 68, 45-50.	0.8	0
287	Phase 3 International Trial of Adjuvant Whole Brain Radiotherapy (WBRT) or Observation (OBS) Following Local Treatment of 1-3 Melanoma Brain Metastases (MBMs). International Journal of Radiation Oncology Biology Physics, 2019, 105, S139-S140.	0.4	0
288	Widespread pulmonary invasion by malignant pleural mesothelioma: an important diagnostic consideration. Respirology Case Reports, 2020, 8, e00675.	0.3	0

#	ARTICLE	IF	CITATIONS
289	New and old treatments for malignant mesothelioma: not just immunotherapy. <i>Lancet Respiratory Medicine</i> , 2021, 9, 547-549.	5.2	0
290	CONFIRMing single-drug immune checkpoint blockade efficacy in mesothelioma. <i>Lancet Oncology</i> , The, 2021, 22, 1485-1487.	5.1	0
291	SU-E-J-96: Prognostic Value of Automatically Segmented Lung Volumes during Chemotherapy for Patients with Mesothelioma. <i>Medical Physics</i> , 2011, 38, 3464-3464.	1.6	0
292	Phase II trial of BNC105P as second-line chemotherapy for advanced malignant pleural mesothelioma (MPM): Australasian Lung Cancer Trials Group and NHMRC Clinical Trials Centre Collaboration.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7079-7079.	0.8	0
293	Usefulness of medical oncologists's estimates of survival time in people with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9087-9087.	0.8	0
294	Activation of Immune-Mediated Tumor Cell Death by Chemotherapy. , 2013, , 373-399.		0
295	Clinical characteristics of desmoplastic pleural malignant mesothelioma: A case series of 19 patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e18545-e18545.	0.8	0
296	Evaluating the utility of the QUAL-EC in the clinical care of patients with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18204-e18204.	0.8	0
297	Evaluating the utility of the QUAL-EC in the clinical care of patients with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21507-e21507.	0.8	0
298	Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8568-8568.	0.8	0
299	Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8566-8566.	0.8	0
300	INNV-08. LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY. <i>Neuro-Oncology</i> , 2021, 23, vi106-vi107.	0.6	0
301	RTID-05. THE MULTI-ARM GLIOBLASTOMA AUSTRALASIA (MAGMA) TRIAL. <i>Neuro-Oncology</i> , 2021, 23, vi193-vi194.	0.6	0
302	NIMG-49. A PROSPECTIVE, MULTI-CENTRE TRIAL OF FET-PET IN GLIOBLASTOMA PATIENTS - THE TROG 18.06 FIG STUDY: KEY ASPECTS OF IMAGING AND RADIATION ONCOLOGY CREDENTIALING. <i>Neuro-Oncology</i> , 2021, 23, vi140-vi140.	0.6	0
303	Physical activity and glioma: a case-control study with follow-up for survival. <i>Cancer Causes and Control</i> , 2022, 33, 749.	0.8	0
304	DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma - A phase 3 randomized trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8599-TPS8599.	0.8	0
305	PEARL: A randomised phase 3 trial of palliative care early in advanced lung cancers (ALTG/TOGA 13/008).. <i>Journal of Clinical Oncology</i> , 2022, 40, 12020-12020.	0.8	0